Immunotherapeutic options for treatment of malignant melanoma
Supplementum 01/2019 Imunoterapie
MUDr. Ondřej Kodet, Ph.D.1,2,3
1 Dermatoveneroíogická klinika 1. LF UK a VFN, Praha
2 Anatomický ústav 1. LF UK, Praha
3 Biotechnologické a biomedicínské centrum AV ČR a UK, Vestec
SUMMARY
Melanoma belongs to significantly immunogenic tumors, allowing for immunological approaches. Melanoma immunotherapy is possibly used in adjuvant administration as well as in metastatic disease. Interferon alpha is used for adjuvant treatment without a significant effect in long-term follow-up. More recently, checkpoint inhibitors (anti-CTLA4, PD1/PD-L1) are used in clinical trials also for adjuvant treatment, which are already standard in metastatic disease. The work discusses the most recent clinical trials and points to the possibilities of combined therapy with targeted therapy. New approaches and future directions for immunotherapy of melanoma are also discussed.
KEY WORDS
melanoma, adjuvant therapy, interferon alpha, checkpoint inhibitors
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...